Oruka Therapeutics

Oruka Therapeutics, Inc. functions as a biotechnology firm primarily dedicated to creating groundbreaking monoclonal antibody therapies. These treatments are designed to address Psoriasis (PsO) along with various other inflammatory and immunological (I&I) conditions. Its current development portfolio includes ORKA-001 and ORKA-002. The company's main operations are based in Menlo Park, CA.